Kathryn C Zoon sold $63k of EBS
director at Emergent BioSolutions Inc.. 7,086 shares at an average of $8.87, traded Aug 15, 2025, filed Aug 18, 2025.
Score components
- +15RoleDirector
- +8Trade size$63k at market
- 0Share of holdings soldSold 9.0% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-040670, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 15, 2025 | SOpen-market sale Common Stock10b5-1 | -7,086 | $8.87 | $63k | 71,799 | Aug 18, 2025 |
Related signals
Other insiders at Emergent BioSolutions Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $126k 17,800 shares | -14% | |
| 3Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $20k 3,000 shares | -2% | |
| 18Weak | EBSsell Emergent BioSolutions Inc. | Ronald Richard director | $263k 21,984 shares | -21% | |
| 20Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $188k 17,801 shares | -13% | |
| 12Weak | Emergent BioSolutions Inc. | Sujata Tyagi Dayal director | $86k 8,552 shares | -9% | |
| 14Weak | Emergent BioSolutions Inc. | Coleen Glessner EVP, Quality & Ethics, and CPL | $306k 30,608 shares | -17% | |
| 31Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $68k 7,844 shares | -5% | |
| 2Weak | Emergent BioSolutions Inc. | Keith Katkin director | $49k 7,844 shares | -8% | |
| 54Moderate | EBSbuy Emergent BioSolutions Inc. | Joseph C Papa President and CEO | $350k 60,000 shares | +21% | |
| 35Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $57k 10,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.